CD4 + T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
Cancer Medicine · 2025
DOI: 10.1002/cam4.70508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Luis Gil-de-Gómez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, The Children's Hospitial of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Dendritic Cells, CD4-Positive T-Lymphocytes, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hyundai Hope on Wheels Scholar Award, Richard and Sheila Sanford Endowed Chair, Love for Lucy Always Foundation.
Abstract (Originalsprache)
Background
Single antigen (Ag)‐targeted immunotherapies for acute lymphoblastic leukemia (ALL) are highly effective; however, up to 50% of patients relapse after these treatments. Most of these relapses lack target Ag expression, suggesting targeting multiple Ags would be advantageous. Materials & Methods The multi‐Ag immune responses to ALL induced by transducing cell lines with xenoAgs green fluorescent protein and firefly luciferase was elucidated using flow cytometry, ELISA, and ELISpot assays.
Results
In our model, leukemia responsiveness correlates with in vivo CD4+ T cell activation and DC maturation, supporting a role for DC licensing. In contrast, tolerance is characterized by in vivo increased expression of negative immune checkpoints (IC) which may suppress rather than license DC. In vitro assays confirm the ability of CD4+ T cells from leukemia‐responsive mice to promote robust maturation of naïve bone marrow DC in the presence of non‐immunogenic leukemia antigens.
Conclusion
Together these findings support a CD4+ T cell‐mediated mechanism of DC licensing to promote multi‐Ag immune responses that may augment current targeted immunotherapies and avoid relapses in treated children with ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, The Children's Hospitial of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Molecular Biology, University of Cantabria School of Medicine, Santander, Cantabria, Spain.
- Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
- Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Luis Gil-de-Gómez, Stephan A Grupp, Gregor S D Reid, Alix E Seif
Förderung
- Hyundai Hope on Wheels Scholar Award
- Richard and Sheila Sanford Endowed Chair
- Love for Lucy Always Foundation
Zitieren
APA
Gil-de-Gómez, L., Mattei, J. J., Lee, J. H., Grupp, S. A., Reid, G. S. D., & Seif, A. E. (2025). CD4 + T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response. Cancer Medicine. https://doi.org/10.1002/cam4.70508
Vancouver
Gil-de-Gómez L, Mattei JJ, Lee JH, Grupp SA, Reid GSD, Seif AE. CD4 + T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response. Cancer Medicine. 2025. doi:10.1002/cam4.70508
BibTeX
@article{GildeGmez2025,
author = {Gil-de-Gómez, Luis and Mattei, Joseph J and Lee, Jessica H and Grupp, Stephan A and Reid, Gregor S D and Seif, Alix E},
title = {CD4 + T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70508}
}
EUVIMED